TAVO423 is a FAP × LRRC15 × HYAL trispecific AbEn that effectively degraded HA, delayed tumor growth, and enhanced the efficacy of various therapeutics in an in vivo HA-rich colorectal cancer model. Here, LRRC15 is linked to neoplasm.